John C.

Anistasis Global is a management company for multiple small businesses. As Founder of CEO of Anistasis, I have supported startups by the way of initial capital raise, fractional CEO, investor due diligence, business planning, back- office support, and international business development. Overall combined growth within these companies has experienced an annual growth of over 50% year over year.

I'm a father of 5, 3 of whom have the rare inherited retinal disease Blue Cone Monochromacy. Blue Gen Therapeutics Foundation is the next step towards a treatment for BCM. We humbly stand on the foundation built by millions of invested dollars and countless years of pioneering scientific discovery championed by parents, academics, and the industry's best researchers. BGTF is devoted toward bringing this treatment into clinical trials for boys and men around the world with the debilitating disease of BCM. Using a licensed technology built on the 7m8 platform . BGTF-027 (Formerly ADVM-062) will be a single dose Intravitreal Gene Therapy. Our robust IND ready program has received ODD status, has ample GMP lot, and has compelling preclinical tolerability and efficacy. The program is gaining momentum towards the exciting possibility of a safe, efficacious treatment for BCM. I act as a catalyst and leader to join the talent and resources toward this bold endeavor so that not only my precious sons, Father-in-law, and nephews may have improved vision but that we may offer this treatment at an affordable, reimbursable, cost to the several thousand around the world.

Founded in 2013, Covenant Testing currently has operations in the Permian, Niobrara-DJ, and Powder River Basins, and the Bakken, Eagle Ford and Haynesville Shales. A market leader for the upstream oil and gas industry, Covenant provides pressure control, flowback, production services and reservoir analytics, with a focus on horizontal and pad drilling.

Led the company to be the number one well testing company in the United States in less than two years with an outsized return on capital.